Get started
PYPL eyes on $86.63: Golden Genesis barrier going into earningsFollow up to my previous plot to catch dip (click). Earning report due within the day of posting here. 2 golden fibs being tested, pair could top the wave. Recent break out fib is key support to try and hold. $ 84.51 is a local golden that wanted to end wave. $ 86.63 is a Golden Genesis fib, very likely to react. $ 78.41/42 is the first good support below if it dips. Previous Plot for dip entry: ================================================================== .
NASDAQ:PYPL
by EuroMotif
Hims demand zone leading into earningsHims is a position that has a lot of controversy but I am bullish. Lots of volatility rewards the patient. I have added a daily demand zone as we approach earnings and the conclusion of the election. We have already seen a very strong bounce from the buy zone and I have played my cards accordingly. I love seeing the stochastic RSI this low leading into earnings. Note the rising average volume as well. My plan: I have spot shares I plan to hold long term During the 15% drawdown last week I sold CSP for 11/8 expiration that were aggressive, I will close these at 90% profit Any time we approach 18$ I will sell aggressive CSP
NYSE:HIMSLong
by Apollo_21mil
2
Dexcom Inc. 1. Company Overview and Industry Growth Potential Dexcom Inc. is a prominent player in the medical technology industry, focusing on continuous glucose monitoring (CGM) systems primarily used by individuals with diabetes. The company's flagship product line, the Dexcom G Series, offers real-time glucose monitoring, which significantly improves the quality of diabetes management. The CGM industry is poised for robust growth due to the increasing prevalence of diabetes worldwide and the demand for efficient, non-invasive glucose management solutions. Additionally, advancements in healthcare technology and the growing adoption of digital health tools further support a positive outlook for Dexcom and similar companies in the sector. The market is expected to see continued expansion as more healthcare providers and patients adopt CGM systems, and as new markets open globally. 2. Latest Earnings and Future Forecast Dexcom's most recent earnings data (from the September 2024 report) did not reveal specific results, but typically, the company’s earnings performance has shown consistent revenue growth driven by increased adoption of CGM technology. Analysts often look for key indicators such as growth in user base, geographic expansion, and new product launches or upgrades (e.g., the Dexcom G7) to forecast future revenue. Expectations for Dexcom’s upcoming quarters are positive, with potential growth projected from partnerships, increased reimbursement coverage, and regulatory approvals in new regions. 3. Recent Stock Trends and Capital Flow As of the latest available data (November 3, 2024), the stock price for Dexcom Inc. is reported at $0.00, which may be a placeholder or an indication of unavailability in the dataset. For capital flow on a one-day basis, there appears to be no recorded inflow or outflow data available. This lack of data could limit insights into immediate buying or selling pressure, but typically, Dexcom stock experiences interest from both retail and institutional investors due to its growth potential in the healthcare sector. 4. Analyst Viewpoints and Target Price Industry analysts generally hold an optimistic view on Dexcom’s stock, often assigning a favorable target price that reflects the expected growth trajectory within the CGM market. While specific target price information was not provided, analyst recommendations often emphasize Dexcom’s market leadership, technological edge, and growth potential within a rapidly expanding market. Investment suggestions usually skew bullish, but it is essential to monitor any changes in healthcare regulations or competitive dynamics that may impact this outlook. 5. Bullish and Bearish News Summary Bullish News: Product Innovation: Dexcom’s consistent product upgrades, including the development of smaller, more accurate devices, continue to strengthen its market position. Market Expansion: Increased global focus on diabetes management and new regulatory approvals could expand Dexcom’s market reach, particularly in underserved regions. Bearish News: Competitive Pressure: Dexcom faces strong competition from companies like Abbott with its Freestyle Libre system, which could affect market share. Pricing Pressure and Insurance: Potential issues around insurance reimbursements and pricing strategies could pose challenges to future growth if not managed effectively. Disclaimer The above analysis is based on publicly available information and should not be considered as personalized investment advice. The stock market is inherently volatile, and investors should carefully evaluate their risk tolerance and conduct independent research or consult with a financial advisor before making investment decisions. Please note that the healthcare industry can experience sudden regulatory shifts, and Dexcom's business may be influenced by changes in healthcare policies, competition, and other industry-specific factors.
NASDAQ:DXCMLong
by Joekenstein7
Market Update - 11/3/2024Just follow your rules and not trade! That's what I should have been doing. But well, since I'm a bit addicted to trading and have a fear of missing trades, I'm acting on every signal which is costing me money. Overall not much to talk about as the market is quite weak, lots of failed setups, reversals, breadth is the worst in a while. Lots of earnings coming up next week, as well as elections, so things could also turn around very quickly. Usually the best buying opportunities are also during these times, so need to be vigilant with setups and market action. For now, I'm 90% cash and just waiting. If any of thesetups for next week break out, I will only put on a very small risk, maybe 0.25% of my account. Want to remain cautious until we get a strong bullish signal. My worry is that once that bullish signal comes, I won't be going aggressive enough. Then as the market continues higher and it broadens out, I become more and more invested, exactly doing the opposite of what I should be doing: plunge in at the beginning of trends and peel off as the market goes higher. It's a tough lesson to learn and takes a lot of experience.
NASDAQ:WGS
by BenedekBokor
APPLE Trading Opportunity! BUY! My dear subscribers, My technical analysis for APPLE is below: The price is coiling around a solid key level - 222.92 Bias - Bullish Technical Indicators: Pivot Points Low anticipates a potential price reversal. Super trend shows a clear buy, giving a perfect indicators' convergence. Goal - 229.43 My Stop Loss - 219.19 About Used Indicators: By the very nature of the supertrend indicator, it offers firm support and resistance levels for traders to enter and exit trades. Additionally, it also provides signals for setting stop losses ——————————— WISH YOU ALL LUCK
NASDAQ:AAPLLong
by AnabelSignals
1
AMAZON | AMZN , Jeff is back? While Jeff Bezos, fiancée Lauren Sánchez have star studded engagement party on his $500M yacht Amazon has just reported its Q2 2023 earnings result, EPS of 65 cents is not comparable on YoY basis nor to consensus due to the company booking some gains related to its Rivian Automotive, Inc (RIVN) investment. Revenue of $134.3 billion beat consensus by about 2% while showing a YoY jump by nearly 11%. As an immediate reaction, the stock is up nearly 8% after-hours, although this can turn on a dime.I wrote in my preview that Amazon still remains a revenue story and to pay attention to Q2's actual revenue and Q3's revenue guidance. Amazon hit it out of the park on both counts, with Q2 revenue showing an 11% jump and Q3 guidance of $138 billion to $143 billion, easily upping the consensus of $138.29 billion. As a direct effect of the company reining in on its expenses, Amazon's Free Cash Flow ("FCF") in Q2 2023 improved to almost $8 billon compared to -$23.5 billion in Q2 2022. Headcount is now down 4% YoY.Advertising, which I've highlighted as the next growth driver in many of my past articles, was up 22% YoY. But, more importantly, resumed its upward trajectory on a quarterly basis. Advertising services revenue showed continuous QoQ improvement until the first blip in Q1 2023. Whether Q2's upsurge is a new trend remains to be seen, but it is encouraging that Q2 did not follow Q1 down. I am also glad that my prediction that advertising will cross $10 billion in sales came true.It appears like retail has finally stopped bleeding profusely to avoid wasting all the gains from AWS and Advertising. In my view, retail is just their medium to sell their ecosystem, and this is acceptable to me. Heading into earnings, Amazon stock was almost into the oversold territory with a Relative Strength Index ("RSI") of 37. Revenue beat and guidance should help the stock garner more analyst support in the upcoming days, and I fully expect the stock's almost-oversold conditions to be in the stock's favor as it has plenty of room upwards technically. The after-hours move has also helped the stock clear all of the commonly used moving averages.AWS's revenue and operating income appeared to be on a perennial, mid-double-digit growth trajectory until recently. However, Q2 saw AWS' sales increase by "just" 12% while operating income fell by more than 5%. It is in this context that advertising services becomes even more important. While $22 billion is strong, it fell well short of the $25 billion I predicted, as the company aims to cross $100 billion in 2023 AWS revenue. The stock was already up 50% YTD heading into earnings and the run appears set to continue. I am not complaining as a long, but it shouldn't surprise anyone to see the stock pullback from the highs given the market's shaky behavior the last few days. Overall, Q2 results are much better than Q1, and that shows in the stock's performance, at least as shown in the after-hours price movement. However, Amazon has never been a single quarter or single year story for me. Amazon's ecosystem is enough reason for me to continue believing in the company long-term. The ability to leverage multiple products and services across the entire organization is not something any company can build overnight. In fact, even Amazon has taken nearly 30 years to be the company that it is today
NASDAQ:AMZN
by moonypto
5
BAC - Big Tumble AheadDespite Fed attempts to juice the economy with interest rate drops, looks like the dollar and the US economy in general is set for some reversion to the mean. Many articles claim that the Fed is bankrupt and as longer term interest rates continue to climb, Bank balance sheets are surely in a perilous condition. ANd that's only what we see. So many other off shore, non reportable bank entities are masking the true disaster that bank stocks really are. I held put positions this past year in bank stocks but it has not yet panned out in my favor. Doesn't mean that I'm wrong though. My ideas are usually sound but my timing is seldom spot on. I.e, I've been buying physical gold and silver since 2014. The real challenge is living long enough to see my ideas get realized. As I plan for my 2025 positions, I'll surely be adding some bank puts to my portfolio.
NYSE:BACShort
by AssetDesign
COINBASE | COIN & SECCoinbase shares are up 35% since the SEC sued the crypto exchange for allegedly selling unregistered securities But Coinbase stock has bounced back, rising some 35% after dropping to a low of about $50 on the day that the SEC sued the U.S.’s largest crypto exchange. As of Wednesday morning, shares were trading near $70, and the publicly traded company’s market capitalization has risen to about $16.5 billion. The resurgence of Coinbase mirrors the broader boomerang of the crypto market in June, riding a Wall Streetfueled fever for Bitcoin that has lifted other cryptocurrencies and injected optimism into an industry that was reeling from a battery of enforcement from the federal government. The Coinbase stock has been rallying, the price of Bitcoin has been rallying, and then these two things usually play off of each other. Specifically, Bitcoin’s resurgence is tied to BlackRock’s recent filing of an application for Bitcoin spot exchange-traded fund, a surprising vote of confidence from the US.’s largest asset manager in the world’s largest cryptocurrency by market capitalization. Shortly after BlackRock’s application became public, the price of Bitcoin soared, notching its highest price in more than a year as a slew of other asset managers filed applications for Bitcoin spot ETFs, potentially opening up the cryptocurrency to trillions in dollars from brokerage accounts and pension funds. And where Bitcoin goes, so goes the broader market, as the total market capitalization of all cryptocurrencies jumped from just about $1 trillion to now about $1.17 trillion. BlackRock’s ETF filing was not only a vote of confidence in Bitcoin but also Coinbase. Its application listed the publicly traded crypto exchange as the custodian for holding the trust’s underlying Bitcoin. For them to continue and list Coinbase as a custodian for their ETF was a strong signal that these SEC allegations are not that big of a deal I think the market is telling us…the worst is behind us, as far as U.S. regulatory crackdown is concerned
NASDAQ:COIN
by moonypto
6